BMO Capital Markets assumed coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) in a research note published on Monday morning, The Fly reports. The brokerage issued a market perform rating and a $107.00 price target on the biotechnology company's stock.

Several other equities analysts have also issued reports on the company. Evercore ISI raised their price objective on BioMarin Pharmaceutical to $130.00 in a report on Friday, December 2nd. Wedbush increased their target price on shares of BioMarin Pharmaceutical from $74.00 to $83.00 and gave the stock a neutral rating in a research note on Wednesday, January 11th. Morgan Stanley increased their target price on shares of BioMarin Pharmaceutical from $113.00 to $132.00 and gave the stock an overweight rating in a research note on Tuesday, January 24th. Oppenheimer upgraded shares of BioMarin Pharmaceutical from a market perform rating to an outperform rating and increased their target price for the stock from $92.00 to $110.00 in a research note on Monday, October 31st. Finally, Bank of America increased their target price on shares of BioMarin Pharmaceutical to $200.00 in a research note on Wednesday, January 4th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $119.39.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN stock opened at $112.84 on Monday. The stock's 50-day moving average is $107.14 and its two-hundred day moving average is $95.05. The firm has a market cap of $20.93 billion, a price-to-earnings ratio of 274.33 and a beta of 0.39. BioMarin Pharmaceutical has a 1 year low of $70.73 and a 1 year high of $117.77. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.54 and a current ratio of 5.15.

Insider Activity

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Altshuler Shaham Ltd purchased a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth approximately $25,000. Quadrant Capital Group LLC grew its stake in BioMarin Pharmaceutical by 188.6% in the 2nd quarter. Quadrant Capital Group LLC now owns 355 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 232 shares during the period. Acadian Asset Management LLC grew its stake in BioMarin Pharmaceutical by 395.4% in the 1st quarter. Acadian Asset Management LLC now owns 431 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 344 shares during the period. Capital Wealth Alliance LLC purchased a new stake in BioMarin Pharmaceutical in the 2nd quarter worth approximately $34,000. Finally, Baystate Wealth Management LLC purchased a new stake in BioMarin Pharmaceutical in the 4th quarter worth approximately $41,000. 96.26% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Company Profile

(Get Rating)

BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.

Read More

• Get a free copy of the StockNews.com research report on BioMarin Pharmaceutical (BMRN)
• Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
• Mullen Automotive Stock Gains Momentum On Positive News
• Harley-Davidson Inc. Stock, Is It Time To Buy?
• The Bottom Is In For Meta Platforms, Volatility Is Not Over
• Analyzing Alaska Air's Recent Earnings

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.